Our analyses focused on both qualitative and quantitative parameters, including total amount of WBCs, RNA recovery efficiency, and quantification of BCR-ABL1 and ABL1 gene transcript levels from matched samples of CML patients. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.